石药集团(01093)重组带状疱疹病毒疫苗SYS 6052在中国启动I/II期临床试验

公告速递
Nov 02

石药集团有限公司(01093.HK)11月2日发布自愿性公告称,由集团自主研发的重组带状疱疹病毒疫苗(CHO细胞)SYS 6052已在中国正式启动I/II期临床试验。

公告显示,SYS 6052由水痘-带状疱疹病毒糖蛋白E(gE)蛋白抗原与集团自主开发的新型纳米佐剂系统构成。通过对抗原及佐剂系统的优化,该产品旨在诱导较强的体液免疫和细胞免疫应答。

根据公告,石药集团已于2026年7月收到国家药品监督管理局签发的《药物临床试验批准通知书》,并在获批后开展随机、盲法、对照的I/II期临床试验,以评估该疫苗在40岁及以上人群中的安全性与免疫原性。目前,受试者招募和筛选工作正在推进中。

石药集团表示,将按相关法规要求持续推进临床研究,并在后续阶段及时披露进展信息。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10